Capsugel Expands Global Manufacturing for Finished-Dosage Forms - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Capsugel Expands Global Manufacturing for Finished-Dosage Forms


Capsugel’s Dosage Form Solutions (DFS) business unit will upgrade and expand three of its manufacturing facilities in the United States and Europe, Capsugel announced in a press release. The multimillion-dollar investments broaden the company’s global capabilities to handle hormonal as well as high-potent compounds for soft gelatin and liquid-fill hard capsules (LFHC) in response to a growing demand from its pharmaceutical and health and nutrition customers.
The expansions are part of the implementation of the DFS unit’s Lipidex technology platform, which was launched in June 2013.

At the Ploermel facility in France, the company will increase containment capacity to handle hormonal as well as high-potent compounds in softgel manufacturing. Upgrades include a high-precision dosing system and high-speed capsule printing capability. At the Livingston facility in the United Kingdom, Capsugel will add laboratory space, equipment, and analytical scientists. The latest generation CFS 1500 capsule filling and sealing machine, which incorporates proprietary Fusion technology, has been installed, and the proprietary lipid expert system has been incorporated into the team’s finished dosage form development process. At the Greenwood facility in the US, the company commissioned and validated a commercial-scale liquid-fill encapsulation unit for pharmaceutical applications. Installation of commercial-production capability for the new solid-lipid-pellet (SLP) technology has also been initiated. SLP technology is currently being used on select customer development projects as a unique lipid-based formulation option for bioenhancement and other formulation issues.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here